Breast cancer drug deemed too expensive for use in England

The NHS drugs watchdog in England has rejected a treatment that can extend the lives of some women with an advanced form of breast cancer because it is too expensive.

The drug, Kadcyla, costs around £90,000 per patient.

Its makers, Roche, have offered a discount but the National Institute of Health and Care Excellence (NICE) said the new price - which is not being disclosed - made little difference.

Hugh Pym reports.